Coriolis Pharma, a global service provider for formulation research and development of biopharmaceuticals and vaccines, has announced the opening of its ATMP development facilities under biosafety level S2 (BSL2 / S2).
After one year of re-construction, the facilities, in close proximity to the company’s headquarters in Martinsried, will significantly increase its capabilities for ATMP development. Formulation development for ATMPs, including cell culture activities, particle characterisation, particle identification and forensic, analytical ultracentrifugation and a lyophilisation development centre, will be available all under biosafety level 2, for Coriolis’ clients and partners.
“The new location with innovative labs and offices will be able to accommodate in the future more than 100 scientific employees,” said Dr Michael Wiggenhorn, CEO of Coriolis Pharma.” With this expansion, we will meet the increasing demand for formulation development and analytical characterisation of ATMPs.”
Similar to mRNA vaccines, ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program, also exploring lyophilisation as an option, can improve this situation, Coriolis claims.
In 2018, the company started strengthening its scientific expertise and services for ATMPs with a dedicated formulation unit for ATMPs and scientific collaborations. The opening of these re-constructed facilities marks the next step in the organic growth of the company.
“Having all our S2 activities in a dedicated and tailored facility increases the efficiency of our work procedures and creates a knowledge-hub for our ATMP projects,” explained Dr Gerhard Sax, Business Unit Manager ATMP. “But what excites me the most is that we now have enough space to test and implement even more new and emerging technologies right under S2.”
